- Library Home /
- Search Collections /
- Open Collections /
- Browse Collections /
- UBC Faculty Research and Publications /
- Outpatient versus inpatient intravenous antimicrobial...
Open Collections
UBC Faculty Research and Publications
Outpatient versus inpatient intravenous antimicrobial therapy : a population-based observational cohort study of adverse events and costs Staples, John; Ho, Meghan; Ferris, Dwight; Hayek, Jan; Liu, Guiping; Tran, Karen C.; Sutherland, Jason M.
Abstract
BACKGROUND: Bacterial infections such as osteomyelitis and endocarditis routinely require several weeks of treatment with intravenous (IV) antimicrobials. Outpatient parenteral antimicrobial therapy (OPAT) programs allow patients to receive IV antimicrobials in an outpatient clinic or at home. The outcomes and costs of such treatments remain uncertain. METHODS: We conducted a retrospective observational cohort study over a 5-year study interval (June 1, 2012, to March 31, 2018) using population-based linked administrative data from British Columbia, Canada. Patients receiving OPAT following a hospitalization for bacterial infection were matched based on infection type and implied duration of IV antimicrobials to patients receiving inpatient parenteral antimicrobial therapy (IPAT). Cumulative adverse events and direct healthcare costs were estimated over a 90-day outcome interval. RESULTS: In a matched cohort of 1,842 patients, adverse events occurred in 35.6% of OPAT patients and 39.0% of IPAT patients (adjusted odds ratio, 1.04; 95%CI, 0.83-1.30; p=0.61). Relative to IPAT patients, OPAT patients were significantly more likely to experience hospital readmission (30.5% vs 23.0%) but significantly less likely to experience C. difficile diarrhea (1.2% vs 3.1%) or death (2.0% vs 8.8%). Estimated mean direct healthcare costs were $30,166 for OPAT patients and $50,038 for IPAT patients (cost ratio, 0.60; average cost savings with OPAT, $17,579; 95%CI, $14,131-$21,027; p<0.001). CONCLUSION: Outpatient IV antimicrobial therapy is associated with a similar overall prevalence of adverse events and with substantial cost savings relative to patients remaining in hospital to complete IV antimicrobials. These findings should inform efforts to expand OPAT use.
Item Metadata
Title |
Outpatient versus inpatient intravenous antimicrobial therapy : a population-based observational cohort study of adverse events and costs
|
Alternate Title |
Observational cohort study of OPAT versus IPAT
|
Creator | |
Contributor | |
Publisher |
Oxford Academic
|
Date Issued |
2022-03-31
|
Description |
BACKGROUND: Bacterial infections such as osteomyelitis and endocarditis routinely require
several weeks of treatment with intravenous (IV) antimicrobials. Outpatient parenteral
antimicrobial therapy (OPAT) programs allow patients to receive IV antimicrobials in an
outpatient clinic or at home. The outcomes and costs of such treatments remain uncertain.
METHODS: We conducted a retrospective observational cohort study over a 5-year study
interval (June 1, 2012, to March 31, 2018) using population-based linked administrative data
from British Columbia, Canada. Patients receiving OPAT following a hospitalization for
bacterial infection were matched based on infection type and implied duration of IV
antimicrobials to patients receiving inpatient parenteral antimicrobial therapy (IPAT).
Cumulative adverse events and direct healthcare costs were estimated over a 90-day outcome
interval.
RESULTS: In a matched cohort of 1,842 patients, adverse events occurred in 35.6% of OPAT
patients and 39.0% of IPAT patients (adjusted odds ratio, 1.04; 95%CI, 0.83-1.30; p=0.61).
Relative to IPAT patients, OPAT patients were significantly more likely to experience hospital
readmission (30.5% vs 23.0%) but significantly less likely to experience C. difficile diarrhea
(1.2% vs 3.1%) or death (2.0% vs 8.8%). Estimated mean direct healthcare costs were $30,166
for OPAT patients and $50,038 for IPAT patients (cost ratio, 0.60; average cost savings with
OPAT, $17,579; 95%CI, $14,131-$21,027; p<0.001). CONCLUSION: Outpatient IV antimicrobial therapy is associated with a similar overall
prevalence of adverse events and with substantial cost savings relative to patients remaining in
hospital to complete IV antimicrobials. These findings should inform efforts to expand OPAT
use.
|
Genre | |
Type | |
Language |
eng
|
Date Available |
2023-04-19
|
Provider |
Vancouver : University of British Columbia Library
|
Rights |
Attribution-NonCommercial-NoDerivatives 4.0 International
|
DOI |
10.14288/1.0413606
|
URI | |
Affiliation | |
Citation |
Staples JA, Ho M, Ferris D, Hayek J, Liu G, Tran KC, Sutherland JM. Outpatient versus inpatient intravenous antimicrobial therapy: a population-based observational cohort study of adverse events and costs. Clin Infect Dis. 2022 Apr 19:ciac298
|
Publisher DOI |
10.1093/cid/ciac298
|
Peer Review Status |
Reviewed
|
Scholarly Level |
Faculty; Researcher
|
Rights URI | |
Aggregated Source Repository |
DSpace
|
Item Media
Item Citations and Data
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International